The Evidence
Whilst the methodology of most of the available studies is reasonable, their usefulness is limited due to most being experimental trials, and all having low numbers of participants. The use of experimental animals with defined infection periods limits extrapolation to general practice where the chronicity of infection is unknown, especially in stray or shelter cats. Feline chlamydophilosis has attracted a reasonable amount of research interest, and various antibacterial regimes have been trialled: doxycycline, co-amoxiclavpotentiated amoxicillin, enrofloxacin, pradofloxacin, azithromycin, roxithromycin, as well as topical fusidic acid and chlortetracycline. In the case of potentiated amoxicillinco-amoxiclav enrofloxacin and pradofloxacin, these trials were funded by manufacturers of veterinary-licensed versions of these compounds. Nevertheless, from the studies available, systemic doxycycline has shown repeated and significant superiority to other antibiotics in both treating the disease and preventing recrudescence, if a course of sufficient length is administered.
Summary of the evidence 1. Sykes (1999)
Population: Experimental colony cats aged 10-12 months weighing approximately 5kg.
Sample size: 8 cats (3 neutered males, 5 entire females).
Intervention details:  All cats pre-infected with feline herpes virus 3 months pre-trial and asymptomatic.  All cats infected with cultured C. psittaci via cornea and after 6 days split into one of three treatment groups: o 4 cats treated with doxycycline 5mg/kg PO q12h for 21 days. o 4 cats left untreated.  Monitoring of response to treatment:
o PCR and culture from conjunctival swabs daily (objective).
Clinical bottom line
Based on the current evidence, oral doxycycline (10mg/kg PO q24h or 5mg/kg PO q12h) for at least 21 days represents the most efficacious treatment, both in terms of clinical improvement and permanent clearance of Chlamydophila felis infection in cats. In chronic infections, or where the duration of disease is unknown, a longer treatment course of 28 days is indicated. There is limited evidence that coamoxiclav (12.5-22 .5mg/kg q12h PO) may be used as an alternative, though a treatment period of at least 30 days is required.
o Clinical signs of infection (non-blinded except for day 9 when an outside clinician blinded to treatment groups used).  Separate rooms for each group.  All treated cats euthanised on day 41, all untreated on day 64, and tissue submitted for chlamydial DNA PCR analysis.
Study design: Non-randomised, non-blinded controlled trial.
Outcome studied:  Comparison of PCR versus culture in diagnosis.
 Investigate whether shorter course of doxycycline for 28-42 days is sufficient to clear infection with C psittaci.  Investigate possible sites of persistent infections following conjunctival clearance.
Main findings: (relevant to PICO question):
 Doxycycline-treated cats:
o Rapid improvement in clinical signs, average duration of signs 9.3 days. o PCR negative after 8 days on average. o Remained PCR/culture negative and disease free following treatment end until euthanasia on day 42.  Untreated cats showed signs for 30 days on average, PCR positive for 30.5 days on average.
Limitations:  Insufficient numbers to answer all three questions.  Very small study numbers (4 treated cats) which preclude the strong conclusion that 21 days of doxycycline is sufficient.  Short follow-up of 14 days post-treatment cessation.  Clinical signs reported in untreated groups correlate poorly with natural infections, with cats in the study developing a severe rhinitis. This suggests a particularly virulent experimental strain and the study does not detail whether the inoculum was a field or experimental isolate. Limits extrapolation to field cases.  Use of experimental colony cats limits extrapolation to field or natural infection. This represented a mono-infection, compared to field infections, where multiple infections, infectious dose, strain variation, genetic diversity of the cats and nutritional plane could impact on severity of infection and response to treatment.  Only a single blinding event at day 9 with an outside clinicianrest of clinical sign logging was by unblinded investigators.  Questionable use of an untreated group -these cats lost weight, had reduced appetite and generally suffered for an extended period with the disease. The authors' aims regarding treatment were to ascertain a shorter course of doxycycline so different treatment length groups could have been used.
Sparkes (1999)
Population: Pathogen-free experimental colony cats aged 4-11 months.
Sample size: 24 (21 entire females, 3 neutered males).  Use of clinical scoring is subject to subjective bias, especially as the treatment groups were not blinded to the investigators.  Culture of chlamydial organisms is less sensitive for detecting chlamydial organisms than PCR, but has the advantage of only identifying live bacteria.  No long-term follow-up, so the persistence of freedom from infection in the doxycycline/fusidic acid and chlortetracycline groups could not be assessed.  Funded in part by producers of fusidic acid eye ointment at that time (Leo Laboratories) -theoretically fusidic acid (working on primarily gram-positive organisms) would have no effect on gram-negative chlamydial organisms.
Sturgess (2001)
Population: Pathogen-free experimental colony cats aged 5 months.
Sample size: 24 (13 females, 11 males).
Intervention details:  Inoculated with a field strain of C. psittaci via the cornea. o Culture from conjunctival swabs taken three times a week (objective) to generate a chlamydial isolation score. o Clinical scoring of disease (subjective but investigator blinded to treatment group) including weight and rectal temperatures (objective).  Trial formally concluded after 91 days and cats observed daily for 6 months after this.
Study design:
Randomised, single-blinded controlled trial.
Outcome studied: Comparison of systemic co-amoxiclav with doxycycline and an untreated control group in the treatment and clearance of C psittaci infection in experimentally infected cats.
Main findings: (relevant to PICO question):
 Doxycycline and co-amoxiclav groups versus placebo:
o Isolation scores significantly lower by day 9 (p<0.01) o Fivefold decrease in clinical scores in first week (p<0.01)  Doxycycline group showed no recurrence after treatment end, demonstrating efficacy in clearing acute infections.  Co-amoxiclav showed efficacy in acute infections, but with high rate of recurrence (62.5%) between 14-20 days after treatment end.  Co-amoxiclav given for 30 days in chronic disease model cats (formerly placebo) and recurrent cats (following initial 19 days treatment) cleared infection with no recurrence.
Limitations:  Small number of participants per treatment group (8) make statistical tests less valid, especially with no confidence intervals stated.  Randomisation method for assigning treatment groups not detailed.  Use of experimental colony cats limits extrapolation to field or natural infection. This represented a mono-infection, compared to field infections, where multiple infections, infectious dose, strain variation, genetic diversity of the cats and nutritional plane could impact on severity of infection and response to treatment.  Culture is less sensitive than PCR for the detection of chlamydial organisms -the 5 cats from the co-amoxiclav treated group that showed recrudescence were likely still infected by the end of treatment, which was not detected by culture.  Clinical scoring is subject to subjective bias, though this was reduced by blinding the investigator to the treatment group.  Author conclusions describe co-amoxiclav as an effective treatment in acute and chronic stages of chlamydiosis, but with the proviso that a further 30 day treatment course may be required after treatment of acute phase. This would mean a 49 day treatment course versus 19 days for doxycycline.  Co-amoxiclav is a time-dependent antibiotic, so treating at 0900 and 1700 is likely suboptimal in maintaining MIC values in conjunctivae for sufficient periods.  No investigation into the effects of doxycycline in chronic chlamydophilosis.  Funded by Pfizer Animal Health, manufacturers of a licensed coamoxiclav preparation for cats.
Owen (2003)
Population: Pathogen-free experimental colony cats aged 5-6 months.
Sample size: 9 (3 entire females, 6 neutered males).
Intervention details:  Inoculated with field strain of C felis via the cornea o Culture from conjunctival swabs (objective). o Clinical scoring of disease (subjective, but investigator blinded to treatment group).  Cats housed in 2 rooms, with one cat from the untreated group and one from doxycycline group in each room and the rest from azithromycin group.  Monitored for 6 months post-trial for recurrence.
Study design: Randomised, single-blinded controlled trial.
Outcome studied: Determination of the efficacy of azithromycin compared to doxycycline-treated controls for the treatment of C felis infection in experimentally infected cats. Limitations:  Small numbers precluded statistical analysis.  Randomisation method for assigning treatment groups and housing not detailed.  Experimental colony cats, due to their husbandry, may possess a less robust immune system than free-living domesticated cats.  Housing treated and untreated cats together can lead to crosscontamination and affect culture results.  Culture is less sensitive than PCR for the detection of chlamydial organisms -it is likely the azithromycin cats that were negative on culture remained persistently infected.  Clinical scoring is subject to subjective bias, though this was reduced by blinding the investigator to the treatment group.  Dosage and dosing regime for azithromycin is poorly characterised in cats and the regime used in this study may have negatively affected the results o PCR copy numbers from conjunctival swabs (objective). o Clinical scoring of disease (subjective but investigator blinded to treatment group).  Cats were housed in rooms according to treatment group.  Monitored for 6 months post-trial for recurrence.
Veterinary Evidence
Outcome studied: Assess efficacy of 7-day and 14-day doxycycline treatment courses on the treatment and elimination of C felis using real-time PCR to monitor course of infection and response to treatment.
Main findings: (relevant to PICO question):
 Doxycycline treated groups:
o Rapid decrease in PCR copy numbers and clinical scores within 2 days of treatment and apparent clinical cure by the end of treatment. o All cats showed recurrence of disease after treatment end: 7-day cats within 4-7 days and 14-day cats within 14-21 days.  All cats underwent 21-day rescue treatment: o 8/11 cleared the infection. o 3/11 required second rescue treatment of 28 days. One of these cats was from the 7-day doxycycline group and two of these cats were from the 14-day doxycycline group. o All cats showed no recurrence in the following 6 months since last treatment.  Authors' recommendation is a 28-day course of doxycycline at 10mg/kg PO q24h required for elimination.
Limitations:  Small number of participants means statistical analysis could not be applied.  Use of an untreated group is questionable given previous studies.  Randomisation method for assigning treatment groups and housing is not detailed.  Experimental colony cats, due to their husbandry, may possess a total pages: 16 less robust immune system than free-living domesticated cats.  Clinical scoring is subject to subjective bias, though this was reduced by blinding.  PCR does not necessarily detect active infection as it can also pick up dead bacterial material.  Authors' recommendation is not fully supported by the results.
It is based on 3 cats failing to clear the infection following a 21-day rescue treatment, and clearing the infection following a 28-day treatment course. However, issues of resistance and a difference in the disease (acute versus chronic) may have played a role in the lack of elimination in 3 cats undergoing 21-day treatment  Reinfection from other cats, or fomites, rather than true recrudescence could be responsible for the recurrence of clinical disease -housing the cats separately would have avoided this possible confounder. This means that it cannot categorically be said that 7 or 14 day courses of treatment do not fully eliminate infection in some cats.
Gerhardt (2006)
Population: Owned cats presented to University of Munich teaching hospital suffering with conjunctivitis. All were negative for FIV/FeLV, had not been pre-treated with antibacterial agents, and were not showing clinical signs of central nervous system or renal disease.
Sample size: 25 cats.
Intervention details:  Randomly assigned to one of two treatment groups:
o 14 cats enrofloxacin 5mg/kg SQ q24h for 3 days then 15mg enrofloxacin q24h PO for 11 days o 11 cats doxycycline 5mg/kg SQ q12h for 3 days then 5mg/kg PO q12h for 11 days o All cats received bromhexine hydrochloride 0.5mg/kg PO q8h and terbutaline 0.03mg/kg PO q8h for 14 days  All cats were examined on days 1, 5, 10 and 14.  Monitoring of response to treatment: o IFA (immunofluorescence) detection of C felis by conjunctival swabs (objective). o Conjunctivitis scores (subjective). o Modified Karnofsky quality of life scores (subjective).
Study design: Randomised, non-blinded controlled trial.
Outcome studied: Compare efficacy of enrofloxacin and doxycycline in the treatment of conjunctivitis and C felis infection in naturally infected cats, and investigate the pharmacokinetics of enrofloxacin.
Main findings: (relevant to PICO question):

 Enrofloxacin group:
o Generally more rapid improvement in conjunctivitis scores, though similar total improvement in groups by trial end. o Greater improvement in quality of life scores on average than doxycycline.  Both groups showed reduced shedding of C felis but none eliminated the organism during the trial Limitations:  Small numbers make statistical analysis less useful.  Title references treatment of cats with C felis but the hypothesis is treatment of conjunctivitis and C felis infection.  No details of cats' sex, age or weight.  No details on randomisation procedure.  Use of injectable doxycycline for 3 days before starting oral therapy is not common practice.  No details as to whether cats were hospitalised during study or owners were involved in treatment -potential non-compliance.  Only treated for 14 days with no follow-up.  Only 15 cats were positive for C. felis -9 in the enrofloxacin group and 6 in the doxycycline group. However all 25 cats including those not infected with C. felis were included in the results, and not censored.  Modified Kanorfsky scoring for quality of life scores to track clinical improvement is not widely used or well established, and subject to operator bias -it was developed by one of the authors in a previous paper and is an adaption of a human cancer patient scoring system from 1948. No details regarding which clinician was involved in scoring.  IFA is considered the least sensitive method of diagnosing C. 
Hartmann (2008)
Population: Cats presented to University of Munich teaching hospital showing signs of upper respiratory disease or conjunctivitis or both. All were >6months of age, negative for FIV/FeLV, had not been pre-treated with antibacterials in the last 6 weeks, were not showing clinical signs of liver or renal disease and were not pregnant or nursing. Cats were either client-owned (10), farm cats (11) Intervention details:  Cats randomly assigned to one of two groups:
o 17 cats pradofloxacin 5mg/kg PO q24h and placebo q12h o 22 cats doxycycline 5mg/kg PO q12h and placebo q24h.  Treatment for 42 days.  Monitoring of response to treatment:
o PCR for C felis, FHV and Mycoplasma spp. from conjunctival swabs PCR for FCV and Mycoplasma spp. from pharyngeal swabs (objective). o Clinical scoring (subjective but investigators blinded to treatment group). o Modified Kanorfsky quality of life score (subjective).
Study design: Randomised, double-blinded controlled trial.
Outcome studied: Investigate efficacy of pradofloxacin in the treatment of cats with clinical signs of upper respiratory tract disease and its ability to eliminate C felis and Mycoplasma infection in these cats. Limitations:  Small numbers make statistical analysis less useful.
 No details on randomisation procedure.  Apart from the 2 cats in the pradofloxacin group that remained PCR positive throughout, no indication which cats were hospitalised or treated at home, so compliance or chances of reinfection could not be assessed.  No long-term follow up (trial stopped at 42 days).  Rationale for 42 days' treatment is a textbook reference.  PCR is the most sensitive method of finding chlamydial DNA but does not differentiate between live and dead organisms.  Clinical scoring subject to subjective bias.  Modified Kanorfsky scoring for quality of life scores to track clinical improvement is not widely used or well established, and subject to operator bias.  Use of pradofloxacin as a first-line treatment in the treatment of C felis is not compliant with best antibacterial prescribing guidelines.  The recommendation to use pradofloxacin in young cats and those with liver disease as an alternative to doxycyline is not supported by the results. The implied contraindication in young cats is predicated on tooth discolouration which is infrequent and of no obvious clinical significance. for cats and dogs.
Ploneczka-Janeczko (2008)
Population: Privately-owned cats, aged 3-10 years, which had undergone doxycycline therapy and developed vomiting or diarrhoea within the first 3 days of treatment.
Sample size: 14 cats (8 male, 6 female).
Intervention details:  Cats treated with roxithromycin 5mg/kg PO q12h for 28 days then had a treatment-free period of 28 days.  Monitoring of response to treatment:
o PCR from conjunctival swabs (objective).
o Clinical scoring and weekly change in clinical signs (same/increased/decreased).
Study design: Case series.
Outcome studied: Evaluate the clinical efficacy of systemic roxithromycin in treating tetracycline-intolerant cats with chronic conjunctivitis caused by C felis.
Main findings: (relevant to PICO question):
 All cats showed improvement in clinical scores with treatment.  No cats cleared infection, and 9/14 showed increase in DNA copy numbers by end of the study (day 56).
Limitations:  Case series with no controls.  Rare to see C felis in cats of these ages, normally a disease of cats <12 months old so the possibility of co-morbidities is high.  Cats were chronically infected -8 cats had shown signs for >12months, 5 for 6-12 months and 1 for 3-6 months.  PCR is the most sensitive method of finding chlamydial DNA but does not differentiate between live and dead organisms.  Conjunctival samples only taken at beginning and end of trial, so difficult to ascertain if ever PCR-negative.  Clinical scoring subject to subjective bias and a change determined by increase/decrease/same lacks sensitivity.  Relied on owners for compliance.
Appraisal, application and reflection
In all of the studies presented, systemic doxycycline therapy shows consistent efficacy against C felis both in bringing about rapid clinical improvement (however measured) within the first week of treatment, and, when given for a sufficient time period, has the most evidence for permanently eliminating infection. It is this latter aspect that makes it currently the most useful therapy versus other compounds studied (co-amoxiclav, pradofloxacin, enrofloxacin, azithromycin, roxithromycin), which, whilst bringing about clinical improvement appear insufficiently consistent at clearing infection. This is especially pertinent for shelter or stray cats, where C felis is commonplace, and infectious diseases require effective and reliable treatment to prevent spread within the facility.
However, the question of how long a course of doxycycline needs to be is more difficult to answer from the studies available. The different course lengths can be summarised as follows: The evidence available indicates that a 14-day course is insufficient, whilst a 21-day course may be sufficient in acute-stage infections which the experimental trials model. However, in field-infected cats, especially those in which the duration of infection is unknown, such as strays, a longer course may be indicated. In the study by Dean et al (2005) , all the cats required rescue treatment after 7 or 14-day courses of treatment, and could therefore be considered chronically infected -in these, a 28-day course was required to eliminate infection from all cats (though 73% or 8/11 cleared the infection with a 21-day course). In shelters without finances to test for organism clearance, a 28-day course may be considered more appropriate; equally, in owned cats with acute infection, a 21-day course is likely to suffice. However, without more trials with greater participant numbers involving naturally infected cats, firm conclusions cannot be drawn. . However, only co-amoxiclav has been shown to consistently (that is, in all cats) clear infection, though a 30-day course was required for chronically infected cats, and a 19-day course given to acutely-infected cats that showed a high rate (62.5%) of recurrence (Sturgess et al 2001) . Whilst doxycycline should remain the first-line treatment, co-amoxiclav, if given for a sufficient length of time (30 days), is a reasonable alternative.
One of the main weaknesses with the evidence presented here is the use of experimental cats, as their use limits extrapolation of results to field-infected free-living cats. Field infections may occur with greater doses of infectious agent, of different pathogenecity, in the face of multiple infections with other agents or against a background of other disease processes, in cats with greater genetic variation and on a variable nutritional plane. Therefore disease presentation, severity, and response to treatment may not match that seen in the field. For example, in stray or unowned animals, the chronicity of disease is unknown and response to treatment in these cases may be suboptimal, especially where secondary sequelae such as tear-duct scarring has occurred. Cats commonly present with C felis in addition to other pathogens of the upper respiratory tract disease complex (Hartmann et al 2010) ; secondary bacterial infection may complicate the clinical picture and delay resolution especially as tetracyclines appear to have only moderate efficacy against studied isolates (Schulz et al 2006) . However, doxycycline has well-documented anti-inflammatory effects (e.g. Krakauer and Buckley 2003) which may help with improvement of clinical signs associated with viral co-infections Several side-effects of oral doxycycline have been described. In a retrospective study of 168 cats, 13% developed vomiting, 11% diarrhoea, and 6% decreased appetite, and 36-40% showed increases in ALT or ALP during therapy (Schulz et al 2013) . Oesophagitis, oesophageal stricture and tooth discolouration, whilst described elsewhere, (e.g. providing food or water after administration may reduce potential gastrointestinal side effects, whilst others (liver enzyme increase, tooth discolouration) appear clinically insignificant and do not represent valid reasons for not using the drug. 
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